These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

322 related articles for article (PubMed ID: 34539576)

  • 1. Monocarboxylate Transporter 8 Deficiency: From Pathophysiological Understanding to Therapy Development.
    van Geest FS; Gunhanlar N; Groeneweg S; Visser WE
    Front Endocrinol (Lausanne); 2021; 12():723750. PubMed ID: 34539576
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Monocarboxylate transporter 8 deficiency: update on clinical characteristics and treatment.
    van Geest FS; Groeneweg S; Visser WE
    Endocrine; 2021 Mar; 71(3):689-695. PubMed ID: 33650046
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Thyroid Hormone Transporters.
    Groeneweg S; van Geest FS; Peeters RP; Heuer H; Visser WE
    Endocr Rev; 2020 Apr; 41(2):. PubMed ID: 31754699
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Mutations in MCT8 in patients with Allan-Herndon-Dudley-syndrome affecting its cellular distribution.
    Kersseboom S; Kremers GJ; Friesema EC; Visser WE; Klootwijk W; Peeters RP; Visser TJ
    Mol Endocrinol; 2013 May; 27(5):801-13. PubMed ID: 23550058
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Overcoming Monocarboxylate Transporter 8 (MCT8)-Deficiency to Promote Human Oligodendrocyte Differentiation and Myelination.
    Lee JY; Kim MJ; Deliyanti D; Azari MF; Rossello F; Costin A; Ramm G; Stanley EG; Elefanty AG; Wilkinson-Berka JL; Petratos S
    EBioMedicine; 2017 Nov; 25():122-135. PubMed ID: 29111262
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical and Molecular Characteristics of SLC16A2 (MCT8) Mutations in Three Families with the Allan-Herndon-Dudley Syndrome.
    Novara F; Groeneweg S; Freri E; Estienne M; Reho P; Matricardi S; Castellotti B; Visser WE; Zuffardi O; Visser TJ
    Hum Mutat; 2017 Mar; 38(3):260-264. PubMed ID: 27805744
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Neurovascular unit disruption and blood-brain barrier leakage in MCT8 deficiency.
    Guillén-Yunta M; Valcárcel-Hernández V; García-Aldea Á; Soria G; García-Verdugo JM; Montero-Pedrazuela A; Guadaño-Ferraz A
    Fluids Barriers CNS; 2023 Nov; 20(1):79. PubMed ID: 37924081
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Brain Gene Expression in Systemic Hypothyroidism and Mouse Models of MCT8 Deficiency: The Mct8-Oatp1c1-Dio2 Triad.
    Morte B; Gil-Ibañez P; Heuer H; Bernal J
    Thyroid; 2021 Jun; 31(6):985-993. PubMed ID: 33307956
    [No Abstract]   [Full Text] [Related]  

  • 9. Functional analysis of monocarboxylate transporter 8 mutations in Japanese Allan-Herndon-Dudley syndrome patients.
    Islam MS; Namba N; Ohata Y; Fujiwara M; Nakano C; Takeyari S; Miyata K; Nakano Y; Yamamoto K; Nakayama H; Kitaoka T; Kubota T; Ozono K
    Endocr J; 2019 Jan; 66(1):19-29. PubMed ID: 30369548
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Allan-Herndon-Dudley syndrome (AHDS) in two consecutive generations caused by a missense MCT8 gene mutation. Phenotypic variability with the presence of normal serum T3 levels.
    Boccone L; Dessì V; Meloni A; Loudianos G
    Eur J Med Genet; 2013 Apr; 56(4):207-10. PubMed ID: 23419639
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Further Insights into the Allan-Herndon-Dudley Syndrome: Clinical and Functional Characterization of a Novel MCT8 Mutation.
    Armour CM; Kersseboom S; Yoon G; Visser TJ
    PLoS One; 2015; 10(10):e0139343. PubMed ID: 26426690
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Disorder of thyroid hormone transport into the tissues.
    Groeneweg S; Visser WE; Visser TJ
    Best Pract Res Clin Endocrinol Metab; 2017 Mar; 31(2):241-253. PubMed ID: 28648511
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Novel mutations in SLC16A2 associated with a less severe phenotype of MCT8 deficiency.
    Masnada S; Groenweg S; Saletti V; Chiapparini L; Castellotti B; Salsano E; Visser WE; Tonduti D
    Metab Brain Dis; 2019 Dec; 34(6):1565-1575. PubMed ID: 31332729
    [TBL] [Abstract][Full Text] [Related]  

  • 14. AAV9-MCT8 Delivery at Juvenile Stage Ameliorates Neurological and Behavioral Deficits in a Mouse Model of MCT8-Deficiency.
    Liao XH; Avalos P; Shelest O; Ofan R; Shilo M; Bresee C; Likhite S; Vit JP; Heuer H; Kaspar B; Meyer K; Dumitrescu AM; Refetoff S; Svendsen CN; Vatine GD
    Thyroid; 2022 Jul; 32(7):849-859. PubMed ID: 35350867
    [No Abstract]   [Full Text] [Related]  

  • 15. Impact of Early Intervention with Triiodothyroacetic Acid on Peripheral and Neurodevelopmental Findings in a Boy with MCT8 Deficiency.
    Ünsal Y; Hayran G
    J Clin Res Pediatr Endocrinol; 2024 Mar; 16(1):116-122. PubMed ID: 38054413
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical course and images of four familial cases of Allan-Herndon-Dudley syndrome with a novel monocarboxylate transporter 8 gene mutation.
    Kobayashi S; Onuma A; Inui T; Wakusawa K; Tanaka S; Shimojima K; Yamamoto T; Haginoya K
    Pediatr Neurol; 2014 Sep; 51(3):414-6. PubMed ID: 25160547
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Psychomotor retardation caused by a defective thyroid hormone transporter: report of two families with different MCT8 mutations.
    Anık A; Kersseboom S; Demir K; Catlı G; Yiş U; Böber E; van Mullem A; van Herebeek RE; Hız S; Abacı A; Visser TJ
    Horm Res Paediatr; 2014; 82(4):261-71. PubMed ID: 25247785
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [The importance of thyroid hormone transporters].
    Braun D
    Nuklearmedizin; 2015; 54(3):77-81. PubMed ID: 26105714
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Myelination Delay and Allan-Herndon-Dudley Syndrome Caused by a Novel Mutation in the SLC16A2 Gene.
    La Piana R; Vanasse M; Brais B; Bernard G
    J Child Neurol; 2015 Sep; 30(10):1371-4. PubMed ID: 25380603
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Long-Term Efficacy of T3 Analogue Triac in Children and Adults With MCT8 Deficiency: A Real-Life Retrospective Cohort Study.
    van Geest FS; Groeneweg S; van den Akker ELT; Bacos I; Barca D; van den Berg SAA; Bertini E; Brunner D; Brunetti-Pierri N; Cappa M; Cappuccio G; Chatterjee K; Chesover AD; Christian P; Coutant R; Craiu D; Crock P; Dewey C; Dica A; Dimitri P; Dubey R; Enderli A; Fairchild J; Gallichan J; Garibaldi LR; George B; Hackenberg A; Heinrich B; Huynh T; Kłosowska A; Lawson-Yuen A; Linder-Lucht M; Lyons G; Monti Lora F; Moran C; Müller KE; Paone L; Paul PG; Polak M; Porta F; Reinauer C; de Rijke YB; Seckold R; Menevşe TS; Simm P; Simon A; Spada M; Stoupa A; Szeifert L; Tonduti D; van Toor H; Turan S; Vanderniet J; de Waart M; van der Wal R; van der Walt A; van Wermeskerken AM; Wierzba J; Zibordi F; Zung A; Peeters RP; Visser WE
    J Clin Endocrinol Metab; 2022 Feb; 107(3):e1136-e1147. PubMed ID: 34679181
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.